Stakeholder Insight - Inflammatory Bowel Disease - Debate over early aggressive treatment continues
Survey suggests that currently 20% of patients with severe Inflammatory Bowel Disease currently receive an early aggressive treatment approach
© companiesandmarkets.com
10.11.2008 02:41:01 www.companiesandmarkets.com adds new report - Stakeholder Insight - Inflammatory Bowel Disease - Debate over early aggressive treatment continues
(live-PR.com) - www.companiesandmarkets.com/Summary-Market-Repor ..
Introduction
Inflammatory bowel disease (IBD) is a chronic inflammatory condition that affects the gastrointestinal tract causing a number of distressing symptoms such as bleeding, diarrhea and abdominal pain. IBD includes key subsets Crohn's disease and ulcerative colitis, both of which can significantly impact on the quality of life of an individual.
Scope
Analysis of the inflammatory bowel disease market based on a survey
of 180 gastroenterologists supported by key opinion leader interviews
Overview of epidemiology and patient segmentation in IBD
Influences on gastroenterologists' prescribing behavior and their perception of current brands such as Remicade, Humira, Pentasa, Asacol and Lialda
Assessment of outcomes of treatment with Remicade focusing on treatment failure and reasons for failure
Highlights
Clinical guidelines recommend a step-up treatment approach. However, this survey suggests that currently 20% of patients with severe IBD currently receive an early aggressive treatment approach. There is an ongoing debate among Gastroenterologists and this approach will become more commonplace in the future.
Remicade remains the first choice biologic therapy in 80% of biologic-naïve patients. However, Humira has distinct advantages over Remicade that will lead to strong. Humira is positioned as a treatment for Remicade-failure patients, but this survey suggests currently only 30% of these patients go on to receive Humira.
Shire's Lialda (mesalazine), recently launched as a once-daily drug, is perceived by gastroenterologists to perform well on patient compliance. In a drug class where there is little differentiation between brands over efficacy and safety, Lialda will provide a clinical advantage thanks to its improved dosing regimen.
Reasons to Purchase
Target prescribers more effectively, through an understanding of prescribing behavior and influencing factors
Validate new product forecasting based on diagnosis and treatment rates, and the likely rate of uptake for new products
Benchmark brand awareness and perceptions surrounding product positioning in order to formulate competitive lifecycle management strategies
www.companiesandmarkets.com/Summary-Market-Repor ..
Introduction
Inflammatory bowel disease (IBD) is a chronic inflammatory condition that affects the gastrointestinal tract causing a number of distressing symptoms such as bleeding, diarrhea and abdominal pain. IBD includes key subsets Crohn's disease and ulcerative colitis, both of which can significantly impact on the quality of life of an individual.
Scope
Analysis of the inflammatory bowel disease market based on a survey
|
|
Overview of epidemiology and patient segmentation in IBD
Influences on gastroenterologists' prescribing behavior and their perception of current brands such as Remicade, Humira, Pentasa, Asacol and Lialda
Assessment of outcomes of treatment with Remicade focusing on treatment failure and reasons for failure
Highlights
Clinical guidelines recommend a step-up treatment approach. However, this survey suggests that currently 20% of patients with severe IBD currently receive an early aggressive treatment approach. There is an ongoing debate among Gastroenterologists and this approach will become more commonplace in the future.
Remicade remains the first choice biologic therapy in 80% of biologic-naïve patients. However, Humira has distinct advantages over Remicade that will lead to strong. Humira is positioned as a treatment for Remicade-failure patients, but this survey suggests currently only 30% of these patients go on to receive Humira.
Shire's Lialda (mesalazine), recently launched as a once-daily drug, is perceived by gastroenterologists to perform well on patient compliance. In a drug class where there is little differentiation between brands over efficacy and safety, Lialda will provide a clinical advantage thanks to its improved dosing regimen.
Reasons to Purchase
Target prescribers more effectively, through an understanding of prescribing behavior and influencing factors
Validate new product forecasting based on diagnosis and treatment rates, and the likely rate of uptake for new products
Benchmark brand awareness and perceptions surrounding product positioning in order to formulate competitive lifecycle management strategies
www.companiesandmarkets.com/Summary-Market-Repor ..
| Author: |
